Lifeward Ltd. - Ordinary Shares (LFWD)
0.7286
-0.0219 (-2.92%)
NASDAQ · Last Trade: Jul 12th, 10:42 AM EDT
Detailed Quote
Previous Close | 0.7505 |
---|---|
Open | 0.7310 |
Bid | 0.7101 |
Ask | 0.7270 |
Day's Range | 0.6700 - 0.7847 |
52 Week Range | 0.5010 - 4.770 |
Volume | 693,349 |
Market Cap | 45.54M |
PE Ratio (TTM) | -0.2381 |
EPS (TTM) | -3.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,669,918 |
Chart
About Lifeward Ltd. - Ordinary Shares (LFWD)
Lifeward Ltd. is a biotechnology company focused on developing innovative therapeutic solutions for patients with serious medical conditions. The company is dedicated to advancing cutting-edge treatments through rigorous research and clinical trials, aiming to address unmet medical needs and improve patients' quality of life. By leveraging expert knowledge and technology, Lifeward strives to deliver effective, safe, and accessible healthcare options that empower individuals on their health journeys. Their commitment to innovation and patient-centric care positions them at the forefront of the biopharmaceutical industry. Read More
News & Press Releases
Unusual volume stocks are being observed in Monday's session.
Via Chartmill · June 30, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · June 27, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants have an exercise price of $0.65 per ordinary share, are exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date.
By Lifeward Ltd. · Via GlobeNewswire · June 26, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · June 26, 2025
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · June 25, 2025
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 25, 2025
Via Benzinga · June 25, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 25, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the pricing of a public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants will have an exercise price of $0.65 per ordinary share, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about June 26, 2025, subject to the satisfaction of customary closing conditions.
By Lifeward Ltd. · Via GlobeNewswire · June 25, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · June 24, 2025
Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.
By Lifeward Ltd. · Via GlobeNewswire · June 24, 2025
Most recently, Grant was President of the Americas and Chief Commercial Officer of IMRA Surgical, a provider of surgical robotic training.
Via Stocktwits · May 19, 2025
Industry veteran brings 30 years of commercial leadership experience
By Lifeward Ltd. · Via GlobeNewswire · May 19, 2025
MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, Chief Executive Officer, will make a corporate presentation and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 21-22, 2025. Joining him will be Mike Lawless, Chief Financial Officer.
By Lifeward Ltd. · Via GlobeNewswire · May 19, 2025
U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process
By Lifeward Ltd. · Via GlobeNewswire · May 15, 2025
Three-year program examined opportunities to integrate artificial intelligence technology into future generations of ReWalk Exoskeletons
By Lifeward Ltd. · Via GlobeNewswire · May 8, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025.
By Lifeward Ltd. · Via GlobeNewswire · May 7, 2025
Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024
By Lifeward Ltd. · Via GlobeNewswire · April 29, 2025
Cooperation between Lifeward and Beilinson Hospital marks the first step towards a national policy in Israel on Exoskeleton training and procurement
By Lifeward Ltd. · Via GlobeNewswire · April 24, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury
By Lifeward Ltd. · Via GlobeNewswire · April 15, 2025
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · March 13, 2025
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · March 13, 2025